In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with relapsed/refractory multiple myeloma and how often participants use chimeric antigen receptor (CAR) T-cell therapy.
October II 2024
Janet L. Abrahm, MD, FACP, FAAHPM, discussed the high rates of oncologist burnout and compassion fatigue.
Yousef Zakharia, MD, discussed some of the available combination therapies for non–clear cell renal cell carcinoma treatment.
During a Case-Based Roundtable® event, Ursa Brown-Glaberman, MD, discussed options for the treatment of patients with PIK3CA-altered metastatic breast cancer.
During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.
During a Case-Based Roundtable® event, Jennifer L. Atlas, MD, discussed treatment for a patient with basal cell carcinoma who reported challenging adverse events with hedgehog pathway inhibitor.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
